IRIS UniCatt

Gori, Niccolo'
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.410
AS - Asia 1.244
EU - Europa 681
SA - Sud America 237
Continente sconosciuto - Info sul continente non disponibili 56
AF - Africa 43
OC - Oceania 3
Totale 3.674
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.339
SG - Singapore 561
CN - Cina 276
BR - Brasile 190
IT - Italia 140
VN - Vietnam 137
FR - Francia 116
DE - Germania 102
SE - Svezia 72
GB - Regno Unito 59
HK - Hong Kong 41
FI - Finlandia 39
CA - Canada 38
IN - India 38
JP - Giappone 37
ID - Indonesia 35
IE - Irlanda 33
RU - Federazione Russa 26
PL - Polonia 23
KR - Corea 22
MX - Messico 21
SA - Arabia Saudita 19
BD - Bangladesh 18
NL - Olanda 15
IQ - Iraq 13
AR - Argentina 12
ZA - Sudafrica 12
CI - Costa d'Avorio 11
PK - Pakistan 11
ES - Italia 10
AT - Austria 8
VE - Venezuela 8
CZ - Repubblica Ceca 7
EC - Ecuador 7
BO - Bolivia 6
CO - Colombia 6
KE - Kenya 6
TR - Turchia 6
MA - Marocco 5
AL - Albania 4
BE - Belgio 4
CY - Cipro 4
LT - Lituania 4
AE - Emirati Arabi Uniti 3
AU - Australia 3
DZ - Algeria 3
HR - Croazia 3
PA - Panama 3
PE - Perù 3
PS - Palestinian Territory 3
PT - Portogallo 3
RO - Romania 3
UA - Ucraina 3
UZ - Uzbekistan 3
CL - Cile 2
HU - Ungheria 2
IL - Israele 2
JO - Giordania 2
MY - Malesia 2
PH - Filippine 2
UY - Uruguay 2
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CR - Costa Rica 1
DK - Danimarca 1
EG - Egitto 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
IR - Iran 1
JM - Giamaica 1
KG - Kirghizistan 1
KW - Kuwait 1
KY - Cayman, isole 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
NG - Nigeria 1
NI - Nicaragua 1
SC - Seychelles 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TM - Turkmenistan 1
VG - Isole Vergini Britanniche 1
Totale 3.618
Salva come PNG Salva come JPEG
Città #
Singapore 305
San Jose 189
Ashburn 157
Chandler 122
Beijing 60
Hefei 55
Council Bluffs 49
New York 45
Ho Chi Minh City 44
Frankfurt am Main 41
Los Angeles 39
Milan 39
Hong Kong 38
Lauterbourg 38
Tokyo 33
Dublin 32
Jakarta 31
Hanoi 29
Rome 29
Dallas 27
Helsinki 24
Munich 22
St Louis 22
Santa Clara 20
Seoul 20
Boston 19
Chicago 19
Kent 18
London 18
Bremen 17
Paris 16
Boardman 15
São Paulo 15
Warsaw 15
Moscow 14
Amsterdam 13
Montreal 13
Phoenix 13
Hangzhou 12
Princeton 12
Abidjan 11
Brooklyn 11
The Dalles 11
Tukwila 11
Jeddah 10
Lappeenranta 9
Nuremberg 9
Orem 9
Da Nang 8
Denver 8
Roubaix 8
Stockholm 8
Toronto 8
Boydton 7
Hyderabad 7
Mexico City 7
Portsmouth 7
Atlanta 6
Chennai 6
Curitiba 6
Manchester 6
Mumbai 6
Nairobi 6
Ottawa 6
Pune 6
Redwood City 6
Turku 6
Washington 6
Wilmington 6
Wroclaw 6
Agrolândia 5
Charlotte 5
Falkenstein 5
Haiphong 5
Rio de Janeiro 5
San Francisco 5
San Mateo 5
Southampton 5
Vienna 5
Baghdad 4
Brussels 4
Caracas 4
Düsseldorf 4
Johannesburg 4
La Paz 4
Medina 4
Nicosia 4
North Bergen 4
Riyadh 4
Vincennes 4
Bexley 3
Bitonto 3
Brasília 3
Brno 3
Buffalo 3
Bắc Ninh 3
Bến Tre 3
Chiyoda-ku 3
Cleveland 3
Faisalabad 3
Totale 2.085
Salva come PNG Salva come JPEG
Nome #
Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients 131
Assessment of alopecia areata universalis successfully treated with upadacitinib 129
Dupilumab-associated ocular adverse events are predicted by low tear break-up time and correlate with high IL-33 tear concentrations in patients with atopic dermatitis 127
Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis 123
Periocular molluscum contagiosum in an atopic dermatitis patient treated with upadacitinib 121
Dupilumab improves clinical manifestations, symptoms and quality of life in adult patients with chronic nodular prurigo 120
Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy 119
Leser-Trélat sign as a rare manifestation of cutaneous melanoma 119
Biological agents targeting interleukin-13 for atopic dermatitis 116
Evaluation of Upadacitinib efficacy in the treatment of Atopic Dermatitis of sensitive areas 115
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study 114
Histological features of immune cell infiltrate in lesional skin correlate with therapeutic response to dupilumab 111
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry 111
Association between maternal dupilumab exposure and pregnancy outcomes in patients with moderate-to-severe atopic dermatitis: A nationwide retrospective cohort study 105
The psychological burden during COVID-19 pandemic in a cohort of patients affected by moderate-to-severe atopic dermatitis treated with dupilumab 105
Successful response of upadacitinib in different clinical phenotypes of atopic dermatitis 104
Long-term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis in a Real-world Setting: An Interim Analysis Through 48 Weeks of Observation 103
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 103
Analysis of predictive factors influencing dupilumab continuation rate in adult patients with atopic dermatitis: results from an Italian multicenter study 102
Gianotti-Crosti Syndrome after SARS-CoV-2 infection 101
Head and neck atopic dermatitis: still a challenging manifestation in the biologic era 101
A case of disseminated perforating necrobiosis lipoidica 97
Low grade of satisfaction related to the use of current systemic therapies among pustular psoriasis patients: a therapeutic unmet need to be fulfilled 90
Successful response to upadacitinib in the treatment of atopic dermatitis lesions involving sensitive and visible areas resistant to dupilumab treatment 88
Correction to: Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study (Archives of Dermatological Research, (2022), 314, 6, (593-603), 10.1007/s00403-021-02243-w) 86
Comorbidities and treatment patterns in adult patients with atopic dermatitis: results from a nationwide multicenter study 86
Use of upadacitinib in the treatment of moderate to severe atopic dermatitis: patient profiling, dose selection, and therapy modulation, what does real-life teach us? 82
Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study 80
A case of guttate psoriasis during treatment with dupilumab 78
Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study 77
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study 77
Successful response to tralokinumab in patients unresponsive, intolerant or with contraindications to dupilumab and JAK inhibitors: A case series 76
Polymorphic Skin Eruption in a Middle-Aged Man: A Quiz 71
Annular elastolytic giant cell granuloma following herpes zoster infection 70
Patient Satisfaction with Calcipotriol/Betamethasone Dipropionate Cream in Psoriatic Patients Previously Treated With Foam Vehicle 66
National Information Campaign Revealed Disease Characteristic and Burden in Adult Patients Suffering from Atopic Dermatitis 65
Response to the article by Narla et al “Management of inadequate response and adverse effects to dupilumab in atopic dermatitis” 63
Baricitinib for adult atopic dermatitis: real-world effectiveness, safety, and response predictors 22
Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations 20
Totale 3.674
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.692
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.692
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202269 0 0 0 3 4 2 4 6 0 7 18 25
2022/2023359 27 52 24 54 25 38 24 49 47 4 13 2
2023/2024321 15 42 47 31 23 40 24 8 11 8 39 33
2024/2025717 11 10 59 14 75 32 25 15 85 75 189 127
2025/20261.820 231 68 129 238 299 87 321 90 110 133 63 51
2026/2027346 66 128 91 61 0 0 0 0 0 0 0 0
Totale 3.674